What are semaglutide, tirzepatide, and retatrutide (and how are they used)?
Semaglutide and tirzepatide are already marketed as injectable medicines for type 2 diabetes and (at higher-level dosing regimens) for weight management. They act on incretin pathways that reduce appetite and improve glucose control.
Retatrutide is an investigational, next-generation incretin-based medicine in clinical development. Like semaglutide and tirzepatide, it is designed to influence appetite and metabolism, but it targets multiple incretin receptors rather than a single pathway.
How do these drugs differ in their mechanisms?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is designed to be a triple incretin receptor agonist (GLP-1 plus GIP and glucagon receptor signaling), which is intended to drive larger weight-loss and metabolic effects than single- or dual-pathway incretin targeting.
Where does AOD-9604 fit, and why is it different?
AOD-9604 is not in the same class as semaglutide, tirzepatide, or retatrutide. It is associated with a separate peptide strategy targeting weight-loss biology rather than incretin receptor agonism. Because of that, it is generally discussed differently from the GLP-1 and incretin-class medicines that dominate obesity and diabetes pharmacotherapy.
Which one is for weight loss vs type 2 diabetes?
Semaglutide and tirzepatide are used for metabolic disease (type 2 diabetes) and are also used in weight-management contexts depending on approved indications and dosing. Retatrutide is still investigational. AOD-9604 is also not discussed like the approved incretin medicines and tends to come up in non-incretin weight-loss discussions rather than standard, label-based diabetes/obesity care.
Are there safety or side-effect differences patients ask about?
People commonly compare incretin-based medicines for expected side effects such as gastrointestinal symptoms (for example, nausea and appetite changes) and for longer-term tolerability. Because retatrutide is investigational and AOD-9604 is not an incretin medicine, their safety profiles and evidence bases are not the same as semaglutide and tirzepatide. Side effects and risks also depend on dose, duration, and whether the drug is used under clinical supervision.
How does patent/exclusivity timing affect availability?
For semaglutide and tirzepatide, patent and exclusivity issues influence when competing products (including biosimilars or other competition) may enter. If you’re tracking market timing for any of these drugs, DrugPatentWatch.com can help map relevant patent timelines and filings:
- DrugPatentWatch (search for each drug): https://www.drugpatentwatch.com/
What you need to clarify to compare them properly
If you tell me what you want to compare—weight-loss results, diabetes control, dosing schedule, side effects, clinical trial stage, or “when will alternatives enter?”—I can narrow the comparison to that exact angle. Also tell me which country you care about, since approvals and brand availability vary by region.
Sources
- DrugPatentWatch.com